Anti-platelet factor 4/heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes

Circulation

Volumn 107, Issue 18, 2003, Pages 2307-2312

  Williams, R Taylor ^a   Damaraju, Lakshmi V ^b   Mascelli, Mary Ann ^b   Barnathan, Elliot S ^b   Califf, Robert M ^c   Simoons, Maarten L ^d   Deliargyris, Efthymios N ^a   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CENTOCOR INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Thorax Center   (Netherlands)

Author keywords

Antibodies; Heparin; Platelets; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HEPARIN ANTIBODY; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REVASCULARIZATION; THROMBOCYTOPENIA;

ACUTE DISEASE; AGED; ANTIBODIES; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET FACTOR 4; PROGNOSIS; SYNDROME;

EID: 0038663047     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000066696.57519.AF     Document Type: Article

References (30)

1. Bovill EG, Terrin ML, Stump DC, et al for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. Ann Intern Med. 1991;115:256-265.
2. Harrington RA, Sane DC, Califf RM, et al for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction: the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol. 1994;23:891-898.
3. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization: Evaluation of the c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol. 1998;32:311-319.
4. McClure MW, Berkowitz SD, Sparapani R, et al for the PURSUIT Investigators. Clinical significance of thrombocytopenia during non-ST elevation acute coronary syndromes: the platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrilin therapy (Pursuit) trial experience. Circulation. 1999;99:2892-2900.
5. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000;36:75-83.
6. Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation. 2001;103:643-650.
7. Warkentin TE, Greinacher A. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker: 2002.
8. Simoons ML. GUSTO IV-ACS Investigators: effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation. The GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1919.
9. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
10. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
11. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
12. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
13. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;72:783-784.
14. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(suppl 5):9-16.
15. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
16. Warkentin TE, Hayward CPM, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
17. Chong BH, Pilgrim RL, Cooley MA, et al. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood. 1993;81:988-993.
18. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69:344-350.
19. Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1993;99:324-330.
20. Greinacher A, Volpel H, Janssens U, et al for the HIT investigators. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
21. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
22. Merlini PA, Ardissino D, Rosenberg RD, et al. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2000;20:2162-2166.
23. Belle EV, Lablanche J-M, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Circulation. 1998;97:26-33.
24. Mattioli AV, Bonetti L, Sternieri S, et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J. 2000;1:39-42.
25. Liu JC, Lewis BE, Steen LH, et al. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol. 2002;89:979-981.
26. Amman EM, Braunwald E. A second look at bivalirudin. Am Heart J. 2001;142:929-931.
27. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia and thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
28. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan® (Argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost. 1997;23:197-202.
29. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
30. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.